23814-14-4

Basic information

• Product Name: 2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID
• Synonyms: ZERENEX E/6026528;2,3-DIHYDRO-2-OXOBENZIMIDAZOLE-5-CARBOXYLIC ACID;2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID;2-OXO-2,3-DIHYDRO-1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID;1H-Benzimidazole-5-carboxylicacid,2,3-dihydro-2-oxo-(9CI);2-Oxo-2,3-dihydro-1H-benzo[d]iMidazole-5-carboxylic acid;1H-BenziMidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-;2-hydroxy-1H-benzo[d]imidazole-5-carboxylic acid
• CAS NO: 23814-14-4
• Molecular Formula: C₈H₆N₂O₃
• Molecular Weight: 178.14
• EINECS: 200-158-5
• Product Categories: BENZIMIDAZOLE
• Mol File: 23814-14-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID(23814-14-4)
• EPA Substance Registry System: 2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID(23814-14-4)

Safety Data

• Hazardous Substances Data: 23814-14-4(Hazardous Substances Data)

Usage

General Description

2-OXO-2,3-DIHYDRO-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID, also known as Oxcarbazepine, is a chemical compound used as an anticonvulsant and mood stabilizing medication. It works by reducing the excessive electrical activity in the brain that causes seizures and stabilizing mood in conditions like bipolar disorder. Oxcarbazepine is a derivative of carbamazepine, and is believed to be less toxic and have fewer side effects. It is usually taken by mouth in the form of tablets or suspension, and is commonly prescribed for the treatment of epilepsy and other neurological disorders.

Upstream product

• 75-44-5 phosgene 
• 619-05-6 3,4-diaminobenzoic acid 
• 20632-43-3 3-ureido-benzoic acid 
• 57-13-6 urea 

Downstream Products

• 14624-85-2 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carbaldehyde 
• 680188-99-2 1,3-diethyl-5-phenylacetyl-1,3-dihydro-benzoimidazol-2-one 
• 680189-20-2 1,3-diethyl-5-(2-oxo-2-phenyl-ethyl)-1,3-dihydro-benzoimidazol-2-one 
• 459217-12-0 1,3-diethyl-5-(2-oxo-2-m-tolyl-ethyl)-1,3-dihydro-benzoimidazol-2-one 
• 680189-01-9 1,3-diethyl-5-m-tolylacetyl-1,3-dihydro-benzoimidazol-2-one 
• 680189-03-1 1,3-Diethyl-5-[2-(4-fluoro-phenyl)-acetyl]-1,3-dihydro-benzoimidazol-2-one 
• 864523-75-1 1,3-diethyl-5-(4-fluoro-3-methyl-benzoyl)-1,3-dihydro-benzoimidazol-2-one 
• 680189-17-7 1,3-diethyl-5-[2-(4-fluoro-3-methyl-phenyl)-2-oxo-ethyl]-1,3-dihydro-benzoimidazol-2-one 
• 459187-94-1 1,3-diethyl-5-(5-m-tolyl-3H-imidazol-4-yl)-1,3-dihydro-benzoimidazol-2-one 
• 459200-50-1 1,3-Diethyl-5-(3-m-tolyl-1H-pyrazol-4-yl)-1,3-dihydro-benzoimidazol2-one 

Relevant articles and documents

Structural development studies of pyrazoloketone-derived acetyl-CoA carboxylase inhibitors

Acetyl-CoA carboxylase (ACC) plays a key role in fatty acid homeostasis in humans, and inhibitors of ACC are expected to inhibit fatty acid biosynthesis and to activate fatty acid β-oxidation. Therefore, they are considered to be candidates for treatment of metabolic syndrome and related diseases. In this context, an upstream kinase of ACC, adenosine monophosphate-activated protein kinase (AMPK), has also recently emerged as a potential therapeutic target, because it phosphorylates and inactivates ACC. Here, we designed a fused molecule consisting of a pyrazoloketone-type ACC inhibitor and a recently discovered AMPK activator, aiming to develop a novel combined ACC inhibitor/AMPK activator to regulate fatty acid levels. The designed compound was prepared through a convergent synthetic route. This compound and its methyl ester analogue showed potent ACC2-inhibitory activity with IC50 values of 8.8 and 1.3 μM, respectively. Exomethylene derivatives, obtained from an unexpected side reaction during deprotection, also exhibited ACC2-inhibitory activity.